Difference between revisions of "Escitalopram-fluvoxamine"

From Psychiatrienet
Jump to: navigation, search
 
Line 2: Line 2:
 
| from = escitalopram
 
| from = escitalopram
 
| to = fluvoxamine
 
| to = fluvoxamine
| stop = {{StopEscitalopramAtDose}}
+
| stop = {{StopEscitalopram}}
 
| start =  
 
| start =  
 
* No wash-out period is needed.
 
* No wash-out period is needed.
* Start fluvoxamine the next day in normal dosage of 50 mg/day.
+
* '''Day 9: '''start fluvoxamine in normal dosage of 50 mg/day.
 
| info =  
 
| info =  
 
* {{theorSS}}
 
* {{theorSS}}
 
* Fluvoxamine slows the metabolism of escitalopram by inhibition of CYP2C19 and CYP3A4
 
* Fluvoxamine slows the metabolism of escitalopram by inhibition of CYP2C19 and CYP3A4
{{review}}
 
 
}}
 
}}

Latest revision as of 08:58, 28 October 2015

Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from escitalopram to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop escitalopram
  • Before day 1: gradually reduce dosage of escitalopram to a maximum of 10 mg/day, when this dosage is >10 mg/day.
  • Day 1: reduce dosage of escitalopram to a maximum of 5 mg/day.
  • Day 8: stop administration of escitalopram.
Eenrichtingbord.png Start fluvoxamine
  • No wash-out period is needed.
  • Day 9: start fluvoxamine in normal dosage of 50 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluvoxamine slows the metabolism of escitalopram by inhibition of CYP2C19 and CYP3A4
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.